Organon (OGN) earnings history
Most recent quarter
- Fiscal period
- Q1 2026
- Period end
- Mar 31, 2026
- EPS actual
- $0.71
- EPS estimate
- $0.83
- EPS surprise
- −14.32%
- Revenue surprise
- −1.85%
- Revenue
- $1.5B
- Revenue estimate
- $1.5B
- Reported
- Apr 30, 2026
Organon reported Q1 2026 results on April 30, 2026. Earnings per share were $0.71, short of the $0.83 estimate by 14.32%. Revenue was $1.5 billion, 1.85% below a consensus that also rounds to $1.5 billion. Compared with Q1 2025, EPS fell about 30% from $1.02, while revenue was unchanged at the rounded $1.5 billion.
This was the second miss in a row. Q4 2025 came in at $0.63 against a $0.73 estimate, the lowest EPS in the table. Annual EPS has declined each year, from $5.03 in 2022 to $4.14 in 2023, $4.11 in 2024 and $3.66 in 2025, about 27% lower over three years. Revenue stayed between $6.2 billion and $6.4 billion a year over the same span. The highest quarterly EPS in the table came early, at $1.68 in Q2 2021 and $1.67 in Q3 2021. Organon beat the EPS estimate in 14 of the last 20 quarters, but revenue topped the consensus only 3 times.
Q2 results came between August 4 and August 12 in each of the past five years. The table does not yet include a Q2 2026 report, so the next update will show results for that quarter.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2026 | Apr 30, 2026 | $0.83 | $0.71 | −14.32% | $1.5B | SEC |
| Q4 2025 | Feb 12, 2026 | $0.73 | $0.63 | −13.34% | $1.5B | SEC |
| Q3 2025 | Nov 10, 2025 | $0.94 | $1.01 | +7.94% | $1.6B | SEC |
| Q2 2025 | Aug 5, 2025 | $0.95 | $1.00 | +5.43% | $1.6B | SEC |
| Q1 2025 | May 1, 2025 | $0.89 | $1.02 | +14.09% | $1.5B | SEC |
| Q4 2024 | Feb 13, 2025 | $0.87 | $0.90 | +3.79% | $1.6B | SEC |
| Q3 2024 | Oct 31, 2024 | $0.90 | $0.87 | −3.70% | $1.6B | SEC |
| Q2 2024 | Aug 6, 2024 | $1.08 | $1.12 | +4.13% | $1.6B | SEC |
| Q1 2024 | May 2, 2024 | $0.98 | $1.22 | +24.76% | $1.6B | SEC |
| Q4 2023 | Feb 15, 2024 | $0.81 | $0.88 | +8.51% | $1.6B | SEC |
| Q3 2023 | Nov 2, 2023 | $1.05 | $0.87 | −17.17% | $1.5B | SEC |
| Q2 2023 | Aug 8, 2023 | $0.97 | $1.31 | +34.68% | $1.6B | SEC |
| Q1 2023 | May 4, 2023 | $1.17 | $1.08 | −7.35% | $1.5B | SEC |
| Q4 2022 | Feb 16, 2023 | $0.92 | $0.81 | −11.96% | $1.5B | SEC |
| Q3 2022 | Nov 3, 2022 | $1.10 | $1.32 | +19.85% | $1.5B | — |
| Q2 2022 | Aug 4, 2022 | $1.17 | $1.25 | +6.57% | $1.6B | — |
| Q1 2022 | May 5, 2022 | $1.30 | $1.65 | +26.79% | $1.6B | — |
| Q4 2021 | Feb 17, 2022 | $1.24 | $1.37 | +10.23% | $1.6B | — |
| Q3 2021 | Nov 12, 2021 | $1.44 | $1.67 | +15.99% | $1.6B | — |
| Q2 2021 | Aug 12, 2021 | $1.42 | $1.68 | +18.61% | $1.6B | — |
Quarterly revenue
Frequently asked questions
When did Organon (OGN) last report earnings?
Organon last reported on Apr 30, 2026, covering fiscal Q1 2026.
Did OGN beat earnings estimates?
No. Organon reported EPS of $0.71 for Q1 2026 against a $0.83 estimate — a 14.32% miss.
How much revenue did OGN report last quarter?
Organon reported $1.5B in revenue for Q1 2026, against a consensus estimate of $1.5B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.